All Videos

Susan C. Taylor, MD, leads a discussion on approaching patient conversations on vitiligo including understanding patient lifestyle, cultural impact, and the impact on QoL.

Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.

Hilary Baldwin, MD, shares her thoughts on the importance of the Science of Skincare summit and emphasizes the significance of this event in disseminating clinically sound insights into over-the-counter active ingredients.

Gary M. Owens, MD, and Chesahna Kindred, MD, MBA, FAAD, discuss how an optimal multidisciplinary care model for patients with vitiligo can be achieved among providers, pharmacists, and payers.

Experts review the main adverse effects of ruxolitinib, how to monitor for them in your practice, and the key takeaways for clinicians and payers to know about the 2 phase 3 trials that led to the approval of ruxolitinib in vitiligo.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, share their approaches to educating patients on use of steroids for dermatologic conditions, highlighting how they approach pediatric patient populations.

Experts in dermatology discuss the benefits of improved topical steroidal vehicle excipients and their impact on treatment duration and response.

Linda F. Stein Gold, MD; Jayme M. Heim, MSN, FNP-BC; and Darren West, MPAS, PA-C, review the adverse effect profiles of steroidal and nonsteroidal treatments, focusing on hypothalamic pituitary adrenal axis suppression.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, comment on how steroids continue to fit into the topical treatment armamentarium.

Experts in dermatological conditions review the different types of vitiligo and comment on distinguishing features that may be affected as well as differentiating from other hypopigmentation skin conditions.

Susan C. Taylor, MD, and George Han, MD, PhD, provide insight on disease awareness for vitiligo, patient demographics, and factors that contribute to vitiligo etiology.

Peter Lio, MD, reflects on current unmet needs in atopic dermatitis and suggests directions for future research and development.

Peter Lio, MD, shares findings and takeaways from a quantitative study designed to spotlight patient perceptions of current atopic dermatitis treatments and willingness to try new therapies.

Peter Lio, MD, explores the impact of atopic dermatitis on patient quality of life and how it shapes current and future treatment satisfaction.

Gary M. Owens, MD, explains how ruxolitinib fits into the treatment pathway for patients with vitiligo from a payer perspective.

Experts review which patients with vitiligo they would consider using ruxolitinib in.

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Boni Elewski, MD, shares resources for patients with GPP, highlighting a team-based approach to meet the psychological and physical needs of the patient.

Drs Raj Chovatiya and Boni Elewski comment on the future of combination therapy in GPP, highlighting spesolimab.

Experts in dermatology share their insights on how to approach corticosteroid hesitancy in their dermatology patient populations.

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C comment on the practical aspects of utilizing topical corticosteroids, including potency, formulation, administration, and utility.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.

Chesahna Kindred, MD, MBA, FAAD, and Renata Block, PA-C, describe how ruxolitinib works differently from other topicals traditionally used in the treatment of vitiligo.

Experts review the benefits and adverse effects of off-label treatments for patients with vitiligo such as corticosteroids, tacrolimus, pimecrolimus, or calcipotriene (in combination with corticosteroids).

Raj Chovatiya, MD, PHD, and Boni Elewski, MD, discuss long-term treatment selection for a patient whose GPP flare cleared with 1 infusion of spesolimab.

Boni Elewski, MD, reviews a case of a woman in the emergency department with a severe GPP flare.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss pearls and key take-aways from their experience managing atopic dermatitis. Jennifer Holman wraps up discussing anticipated therapeutic developments and unmet needs.